Anna Maria Langkilde

17.6k total citations · 7 hit papers
135 papers, 5.5k citations indexed

About

Anna Maria Langkilde is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Anna Maria Langkilde has authored 135 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Endocrinology, Diabetes and Metabolism, 48 papers in Surgery and 40 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Anna Maria Langkilde's work include Diabetes Treatment and Management (116 papers), Pancreatic function and diabetes (41 papers) and Metabolism, Diabetes, and Cancer (34 papers). Anna Maria Langkilde is often cited by papers focused on Diabetes Treatment and Management (116 papers), Pancreatic function and diabetes (41 papers) and Metabolism, Diabetes, and Cancer (34 papers). Anna Maria Langkilde collaborates with scholars based in United States, United Kingdom and Sweden. Anna Maria Langkilde's co-authors include John J.V. McMurray, Marc S. Sabatine, Glenn M. Chertow, Hiddo J.L. Heerspink, Scott D. Solomon, David C. Wheeler, Peter Rossing, Niels Jongs, Ricardo Correa‐Rotter and Felipe A. Martínez and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Annals of Internal Medicine.

In The Last Decade

Anna Maria Langkilde

133 papers receiving 5.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

2020 355 citations David C. Wheeler, Bergur V. Stefánsson et al. The Lancet Diabetes & Endocrinology profile →
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus

2020 313 citations Thomas A. Zelniker, Marc P. Bonaca et al. Circulation profile →
A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF)

2019 259 citations John J.V. McMurray, David L. DeMets et al. European Journal of Heart Failure profile →
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

2021 237 citations David C. Wheeler, Robert D. Toto et al. profile →
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial

2021 182 citations Scott D. Solomon, Rudolf A. de Boer et al. European Journal of Heart Failure profile →
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF

2021 140 citations Kieran F. Docherty, Pardeep S. Jhund et al. profile →
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction

2021 130 citations David D. Berg, Pardeep S. Jhund et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Maria Langkilde United States	37	3.5k	1.7k	1.5k	1.3k	952	135	5.5k
Shamik Parikh United States	33	4.6k 1.3×	311 0.2×	2.2k 1.4×	2.6k 2.0×	424 0.4×	60	5.9k
Elza Muscelli Italy	34	2.9k 0.8×	1.1k 0.6×	2.0k 1.3×	1.4k 1.1×	360 0.4×	76	4.8k
Valma Harjutsalo Finland	35	2.1k 0.6×	639 0.4×	923 0.6×	376 0.3×	645 0.7×	137	3.9k
Alper Sönmez Türkiye	41	1.1k 0.3×	1.2k 0.7×	918 0.6×	734 0.6×	1.0k 1.1×	169	4.9k
Pedro Iglesias Spain	35	2.5k 0.7×	356 0.2×	751 0.5×	723 0.6×	472 0.5×	219	4.9k
Kyu Yeon Hur South Korea	38	1.7k 0.5×	443 0.3×	1.0k 0.7×	1.2k 0.9×	161 0.2×	185	4.6k
Jeong Bae Park South Korea	32	789 0.2×	1.8k 1.1×	522 0.3×	419 0.3×	132 0.1×	109	3.4k
David Sacerdoti Italy	41	490 0.1×	423 0.2×	1.5k 1.0×	818 0.6×	321 0.3×	167	5.0k
A. Elisabeth Hak Netherlands	24	1.6k 0.5×	672 0.4×	582 0.4×	548 0.4×	590 0.6×	42	4.1k
Robert G. Josse Canada	25	1.4k 0.4×	498 0.3×	1.0k 0.7×	710 0.6×	151 0.2×	44	3.4k

Countries citing papers authored by Anna Maria Langkilde

Since Specialization

Citations

This map shows the geographic impact of Anna Maria Langkilde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Maria Langkilde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Maria Langkilde more than expected).

Fields of papers citing papers by Anna Maria Langkilde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Maria Langkilde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Maria Langkilde. The network helps show where Anna Maria Langkilde may publish in the future.

Co-authorship network of co-authors of Anna Maria Langkilde

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Maria Langkilde. A scholar is included among the top collaborators of Anna Maria Langkilde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Maria Langkilde. Anna Maria Langkilde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bakker, W, Hiddo J.L. Heerspink, Niels Jongs, et al.. (2025). Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKD. Journal of the American Society of Nephrology. 37(1). 101–109. 1 indexed citations

Chertow, Glenn M., Hiddo J.L. Heerspink, Patrick B. Mark, et al.. (2024). Effects of Dapagliflozin in Patients with Membranous Nephropathy. SHILAP Revista de lepidopterología. 4(1). 137–145. 2 indexed citations

Docherty, Kieran F., Rudolf A. de Boer, Jersey Chen, et al.. (2024). Wearable Accelerometer-Derived Measures of Physical Activity in Heart Failure: Insights From the DETERMINE trials. Journal of Cardiac Failure. 31(4). 689–703. 1 indexed citations

Vart, Priya, Jawad H. Butt, Niels Jongs, et al.. (2023). Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty. The Journals of Gerontology Series A. 79(2). 25 indexed citations

Chatur, Safia, Jonathan W. Cunningham, Muthiah Vaduganathan, et al.. (2023). Renal and Blood Pressure Effects of Dapagliflozin in Recently Hospitalized Patients with Heart Failure with mildly reduced or Preserved Ejection Fraction: Insights from the DELIVER Trial. European Journal of Heart Failure. 25(7). 1170–1175. 15 indexed citations

Persson, Frederik, Niels Jongs, Gozewijn D. Laverman, et al.. (2023). Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study. Diabetes Care. 46(3). 602–607. 9 indexed citations

Peikert, Alexander, Parag Goyal, Muthiah Vaduganathan, et al.. (2023). Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status. JACC Heart Failure. 11(10). 1380–1393. 13 indexed citations

Kondo, Toru, Karola Jering, C. Jan Willem Borleffs, et al.. (2023). Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. 147(14). 1067–1078. 5 indexed citations

Vart, Priya, David Z.I. Cherney, Glenn M. Chertow, et al.. (2022). Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia. 65(7). 1085–1097. 35 indexed citations

10.

Furtado, Remo H.M., Itamar Raz, Erica L. Goodrich, et al.. (2022). Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation. 145(21). 1581–1591. 19 indexed citations

11.

McMurray, John J.V., David C. Wheeler, Bergur V. Stefánsson, et al.. (2021). Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. JACC Heart Failure. 9(11). 807–820. 62 indexed citations

12.

Jongs, Niels, Tom Greene, Glenn M. Chertow, et al.. (2021). Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. The Lancet Diabetes & Endocrinology. 9(11). 755–766. 126 indexed citations

13.

Heerspink, Hiddo J.L., Remo Holanda de Mendonça Furtado, Otávio Berwanger, et al.. (2021). Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: Results from the DARE-19 Randomized Controlled Trial. Journal of the American Society of Nephrology. 32(10S). B5–B6. 2 indexed citations

14.

Chertow, Glenn M., Priya Vart, Niels Jongs, et al.. (2021). Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. UCL Discovery (University College London). 80 indexed citations

15.

Berg, David D., Stephen D. Wiviott, Benjamin M. Scirica, et al.. (2021). A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care. 44(11). 2573–2581. 17 indexed citations

16.

Zelniker, Thomas A., Marc P. Bonaca, Remo H.M. Furtado, et al.. (2020). Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation. 141(15). 1227–1234. 313 indexed citations breakdown →

17.

McMurray, John J.V., David L. DeMets, Silvio E. Inzucchi, et al.. (2019). A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF). European Journal of Heart Failure. 21(5). 665–675. 259 indexed citations breakdown →

18.

Furtado, Remo H.M., Marc P. Bonaca, Itamar Raz, et al.. (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 139(22). 2516–2527. 235 indexed citations

19.

Zelniker, Thomas A., David A. Morrow, Ofri Mosenzon, et al.. (2019). Abstract 15670: Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58. Circulation. 2 indexed citations

20.

Langkilde, Anna Maria, et al.. (2013). Abstract 11105: Cardiovascular Safety of the SGLT2 Inhibitor Dapagliflozin: Meta-Analysis With >6000 Patient-Years Exposure. Circulation. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact